Baseline IL-6 independently predicts severe immune-related toxicity and poor survival in advanced gastric cancer treated with immunotherapy
Circulating miRNA‑30a is associated with favorable therapeutic outcome in patients with gastric cancer treated with neoadjuvant chemotherapy.
Neoadjuvant chemotherapy (NAC) represents a cornerstone in the management of locally advanced gastric cancer (GC). The present study investigated circulating microRNA (miRNA)-30a as a potential post‑treatment, response‑associated indicator of therapeutic outcome in patients with GC undergoing NAC. Circulating miRNA‑30a expression was measured in serum samples using quantitative real‑time polymerase chain reaction (RT‑qPCR). NAC‑treated patients were stratified into responders (TRG 0‑2) and non‑responders (TRG 3‑5) according to Mandards criteria, while chemotherapy‑naive (CT‑naive) patients were included as a control group. Circulating miRNA‑30a levels were higher in responders compared to non‑responders. Elevated miRNA‑30a expression was associated with reduced pathological tumor burden, including lower T stage and absence of nodal involvement. ROC analysis demonstrated strong discriminatory performance for distinguishing treatment response. In both univariate and multivariable logistic regression analyses, increased miRNA‑30a expression remained independently associated with treatment response. Furthermore, higher miRNA‑30a levels were associated with improved overall survival. In conclusion, circulating miRNA‑30a is associated with favorable therapeutic outcome in GC and may complement conventional assessment strategies in the post‑treatment setting as a response‑associated indicator.
A reliable, non‑invasive biomarker that predicts response to neoadjuvant chemotherapy could improve postoperative risk stratification and guide treatment decisions for gastric cancer patients, potentially enhancing survival outcomes.
Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.
Related signals
- Precision medicine in gastric cancer
- Gastric cancer
- DESTINY‑Gastric05 Phase 3 Trial of ENHERTU Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer
- Nivolumab/Chemo Yields Long-Term Survival in Advanced Gastric Cancers
- Current Treatment and Recent Progress in Gastric Cancer